The PSMB1 (Proteasome Subunit Beta 1) gene encodes the beta1 subunit of the 20S proteasome core particle, the proteolytic enzyme responsible for degrading ubiquitinated proteins in eukaryotic cells. Located at chromosomal position 6q27, PSMB1 is one of seven beta subunits that form the two inner catalytic rings of the proteasome barrel. This gene is essential for the caspase-like proteolytic activity of the proteasome and plays a critical role in cellular protein homeostasis, with particular importance in post-mitotic neurons where efficient protein quality control is essential for long-term survival.
| Gene Symbol | PSMB1 |
| Full Name | Proteasome Subunit Beta 1 |
| Chromosomal Location | 6q27 |
| NCBI Gene ID | 5689 |
| OMIM | 176848 |
| Ensembl ID | ENSG00000100578 |
| UniProt | P20618 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Multiple System Atrophy |
PSMB1 encodes the beta1 subunit of the 20S proteasome, also known as the epsilon subunit or LMP7-related protein. PSMB1 carries the caspase-like (post-acidic) proteolytic activity of the proteasome, cleaving after acidic amino acid residues. Together with PSMB5 (chymotrypsin-like) and PSMB2 (trypsin-like), PSMB1 forms the three catalytic beta subunits that perform the proteolytic degradation of substrate proteins within the proteasome chamber[1].
The proteasome is essential for cellular protein homeostasis, degrading approximately 80-90% of all intracellular proteins through the ubiquitin-proteasome system (UPS). This includes misfolded proteins, regulatory proteins, and damaged proteins that accumulate during stress, aging, and disease[2].
PSMB1 assembles with six other beta subunits (PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7) to form the two inner heptameric rings of the 20S proteasome. The proteasome has a barrel-like structure:
PSMB1 specifically contributes the caspase-like (post-acidic) proteolytic activity to the proteasome:
In neurons, the proteasome with PSMB1 is critical for:
Proteasome dysfunction is a consistent finding in Alzheimer's disease brain. PSMB1 expression and activity are altered in AD hippocampus and cortex, contributing to:
The substantia nigra in PD shows proteasome impairment, which contributes to:
MSA involves oligodendroglial alpha-synuclein accumulation and neuronal loss. Proteasome dysfunction, including altered PSMB1 expression, has been implicated in the pathogenesis of this atypical parkinsonian disorder[7].
PSMB1 is ubiquitously expressed with high levels in metabolically active tissues:
Targeting PSMB1 and the proteasome is a promising therapeutic strategy:
The study of Psmb1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Groll et al. [Structure of the 20S Proteasome (2000)](https://doi.org/10.1016/S0092-8674(00). 2000. ↩︎
Ciechanover, The Ubiquitin-Proteasome Pathway (2015). 2015. ↩︎
Unno et al. [Proteasome Catalytic Mechanism (2002)](https://doi.org/10.1016/S0092-8674(02). 2002. ↩︎
Tai & Schuman, Proteasome in Synaptic Plasticity (2010). 2010. ↩︎
Gregori et al. Proteasome Dysfunction in AD (1995). 1995. ↩︎
McNaught et al. Proteasome Impairment in PD (2002). 2002. ↩︎
Wakabayashi et al. alpha-Synuclein in Glial Cytoplasmic Inclusions in MSA (1998). 1998. ↩︎